Results 21 to 30 of about 154,929 (213)

TUMOR NECROSIS FACTOR-α INHIBITORS IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS

open access: yesНаучно-практическая ревматология, 2016
The paper provides guidelines for the use of tumor necrosis factor-α  (TNF-α) inhibitors in the treatment of patients with axial spondyloarthritis  (axSpA), including ankylosing spondylitis.
S. A. Lapshina   +18 more
doaj   +1 more source

Two Cases of Cutaneous Adverse Effects Induced by Tumor Necrosis Factor-Alpha Inhibitors

open access: yesCase Reports in Dermatology, 2021
Here, we report two cases of cutaneous adverse effects possibly induced by the use of tumor necrosis factor-alpha (TNF-α) inhibitors. The first case presented alopecia areata (AA) and atopic dermatitis (AD) that developed during the treatment of ...
Ena Masukawa   +3 more
doaj   +1 more source

IMPACT OF THE THERAPY WITH TUMOR NECROSIS FACTOR α INHIBITORS ON THE FREQUENCY OF UVEITIS EXACERBATIONS IN PATIENTS WITH ANKYLOSING SPONDYLITIS

open access: yesНаучно-практическая ревматология, 2014
The course of uveitis in patients with ankylosing spondylitis (AS) does not always correlate with inflammation in the axial skeleton and peripheral joints. Effect of tumor necrosis factor α (TNFα) inhibitors on uveitis has been insufficiently studied yet,
Alla A Godzenko   +4 more
doaj   +1 more source

Inflammatory Cytokine Tumor Necrosis Factor-α Enhances Nerve Growth Factor Production in Human Keratinocytes, HaCaT Cells

open access: yesJournal of Pharmacological Sciences, 2009
The skin lesions of inflammatory skin diseases (e.g., atopic dermatitis or psoriasis) accompany infiltration of inflammatory cells like macrophages, where abnormal sensory innervations and elevation of nerve growth factor (NGF) level are observed.
Koji Takaoka   +2 more
doaj   +1 more source

Tumor necrosis factor α Inhibition for Alzheimer’s Disease

open access: yesJournal of Central Nervous System Disease, 2017
Tumor necrosis factor α (TNF-α) plays a central role in the pathophysiology of Alzheimer’s disease (AD). Food and Drug Administration–approved biologic TNF-α inhibitors are thus a potential treatment for AD, but they do not cross the blood-brain barrier.
Rudy Chang   +2 more
doaj   +1 more source

Transferrin receptor 1‐mediated iron uptake supports thermogenic activation in human cervical‐derived adipocytes

open access: yesFEBS Letters, EarlyView.
In this study, we found that human cervical‐derived adipocytes maintain intracellular iron level by regulating the expression of iron transport‐related proteins during adrenergic stimulation. Melanotransferrin is predicted to interact with transferrin receptor 1 based on in silico analysis.
Rahaf Alrifai   +9 more
wiley   +1 more source

How real is the long-lasting effect of tumor necrosis factor α inhibitors? Focus on immunogenicity

open access: yesСовременная ревматология, 2014
Tumor necrosis factor (TNF) α inhibitors are the most commonly used agents to treat rheumatoid arthritis (RA) and other inflammatory arthropathies.
D.E. Karateev
doaj   +1 more source

TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis

open access: yesFrontiers in Immunology, 2022
With anti-PD-1 antibodies serving as a representative drug, immune checkpoint inhibitors (ICIs) have become the main drugs used to treat many advanced malignant tumors.
Xiaohang Liu   +4 more
doaj   +1 more source

Three phosphatase families form a community: The phosphohydrolases that act upon inositol pyrophosphates

open access: yesFEBS Letters, EarlyView.
Inositol pyrophosphates are energy‐rich signaling molecules that perform critical functions in cells. Three different families of phosphatases hydrolyze the β phosphate of the inositol pyrophosphate molecules: two have narrow specificities and one is promiscuous.
Ronda J. Rolfes
wiley   +1 more source

Effect of tumor necrosis factor-α inhibitors on ambulatory 24-h blood pressure

open access: yesBlood Pressure, 2017
Tumor necrosis factor alpha (TNF-α) inhibitors are increasingly being used in inflammatory rheumatic diseases (IRD). The risk of cardiovascular disease is elevated in patients with IRD and TNF-α inhibitors reduce this risk.
Chagai Grossman   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy